Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2019

View Archived Issues

Cyclacel Pharmaceuticals initiates phase I study of CYC-065 plus venetoclax in patients with CLL

Motor protein myosin drives metastasis

Protein links sleep and sickness

SGL-5213 demonstrates efficacy in preclinical model of impaired glucose tolerance

Novel GPR40 superagonist demonstrates remarkable preclinical efficacy in models of diabetes

Preclinical data presented on PBK-001 vaccine for the treatment of melioidosis

Tripartite motif family-like 2 downregulation reduces oral squamous cell carcinoma growth

CSIC patents new PDE8A inhibitors

FDA issues complete response letter for ALKS-5461 NDA for adjunctive treatment of MDD

GenSight announces 48-week data from RESCUE trial of GS-010 in LHON

Dart NeuroScience discloses PDE7B inhibitors

Oxford University signs option agreement with Blue Water Vaccines for universal influenza vaccine

Roche and Genentech identify RIP-1 inhibitors

Nerviano Medical Sciences synthesizes choline kinase inhibitors

Medshine Discovery presents Rho kinase inhibitors

Phosphorylation study gives insights into Chlamydia

OncoSec updates clinical progress with Tavo

Moderna exercises option for exclusive licensing agreement with Avacta

Tinagl1 protein may be therapeutic in triple-negative breast cancer

Circulating miR-3659 found useful for diagnosing dyslipidemia in patients with obesity

FDA clears IND for phase I/IIa trial of VLPM-01 malaria vaccine

BREEZE-AD1 and AD2 studies of baricitinib in atopic dermatitis meet primary endpoints

Eisai plans single phase III confirmatory study of BAN-2401 in early Alzheimer's

Biohaven plans to advance BHV-3500 into phase II for acute treatment of migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...